Amendments to the Specification:

Please amend the specification as follows:

Please replace paragraph starting at page 1, lines 26-32, with the following rewritten paragraph:

These are major problems in the industrial development of human or humanized chimeric monoclonal antibodies. By way of example, the company Protein Design Labs has suspended phase I/II clinical trials of Remitogen® REMITOGEN® (apolizumab), which is an anti-HLA-DR antibody that may be used for treating cancers of MHC class II-positive cells, in particular B-cell and T-cell leukemias.

Please replace paragraph starting at page 3, line 29 to page 4, line 1, with the following rewritten paragraph:

The invention therefore proposes antibodies which have an activity that is up to 100 times greater than the available antibodies in therapy. In particular, the invention provides an anti-HLD-DR and an anti-CD20 that are significantly more effective than their respective homologue such as Remitogen® REMITOGEN® (apolizumab) and Rutixan® RITUXAN® (Rituximab). The present invention marks a major turning point in the development of antibodies for clinical purposes, by providing a new generation, the effective doses of which in order to obtain 50% activity are much lower than those of the antibodies currently used.

Please replace Table 1 starting at page 8, line 21, and ending at page 10, with the following rewritten Table 1:

Antibody name and trade mark	Company	Target	Indication
Edrecolomab PANOREX (Edrecolomab)	Centocor	anti-Ep-CAM	colorectal cancer
Rituximab RITUXAN (Rituximab)	Idec licensed to Genentech/ Hoffmann la Roche	anti-CD20	B cell lymphoma thrombocytopenia purpura

Trastuzumab HERCEPTIN Trastuzumab	Genentech licensed to Hoffmann la Roche/ Immunogen	anti-HER2	ovarian cancer
Palivizumab <u>SYNAGIS</u> (Palivizumab)	Medimmune licensed to Abott		RSV
Alemtuzumab <u>CAMPATH</u> (Alemtuzumab)	BTG licensed to Schering	anti-CD52	leukemia
ZEVALIN (ibritumomab tiuxetan)	IDEC licensed to Schering	anti-CD20	NHL
Cetuximab IMC-C225 (Cetuximab)	Merck/BMS/ Imclone	anti-HER1	cancers
Bevacizumab AVASTIN (Bevacizumab)	Genentech/ Hoffmann la Roche	anti-VEGFR	cancers
Epratuzumab	Immumedics/ Amgen	anti-CD22	cancers: non-Hodgkin lymphoma
Hu M195Mab	Protein Design Labs	ND	cancers
MDX-210	Immuno-Designed Molecules	ND	cancers
BEC2 (Mitumomab)	Imclone	anti-GD3	cancers
Oregovomab <u>OVAREX</u> (Oregovomab)	Altarex	anti-CA125	Ovarian cancer
Ecromeximab KW-2971 (Ecromeximab)	Kyowa-Hakko	anti-GD	malignant melanoma
ABX-EGF	Abgenix	EGF	cancers
MDX010	Medarex	ND	cancers
XTL 002	XTL bio-pharmaceuticals	ND	anti-viral: HCV
H11 SCFV	viventia biotech	ND	cancers
4B5	viventia biotech	anti-GD2	cancers
XTL 001	XTL biopharmaceuticals	ND	anti-viral: HBV

Atty. Dkt. No. 065691-0389

MDX-070	MEDAREX	Anti-PSMA	Prostate cancer
TNX-901	TANOX	anti-CD23	
IDEC-114	IDEC	inhibition ProteinC	non-Hodgkin lymphoma